Last edition
News about Drug Discovery & Development
FDA Grants Interchangeable Status to Celltrion's Denosumab Biosimilars Stoboclo and Osenvelt
The interchangeability (IC) designation allows Stoboclo and Osenvelt to be substituted at the pharmacy level for their reference biologics without requiring prescriber consultation, in accordance with state pharmacy laws.
Drug Discovery & Development | 31/10/2025 | By Darshana
Boehringer Ingelheim Acquires Licence from Kyowa Kirin to Develop Treatment for Autoimmune Diseases
Boehringer Ingelheim has acquired a licence from Kyowa Kirin to develop a small molecule programme targeting autoimmune diseases. The collaboration aims to address significant unmet medical needs and strengthen Boehringer’s pipeline of innovative therapies for patients with inflammatory and immune-related conditions.
Drug Discovery & Development | 31/10/2025 | By Dineshwori
ModeX and Regeneron Partner to Develop Multispecific Antibodies
ModeX Therapeutics has entered into a research collaboration with Regeneron to develop multispecific antibodies capable of targeting multiple biological pathways within a single molecule. The partnership, valued at over USD 1 Billion, if multiple assets advance, aims to accelerate innovation across select therapeutic areas.
Drug Discovery & Development | 30/10/2025 | By Dineshwori
Roche Receives CE Mark for Elecsys Dengue Antigen Test, Enhancing Global Diagnostic Capabilities
This milestone represents a significant advancement in efficiency and reliability for laboratories worldwide, helping healthcare systems address the escalating global dengue crisis.
Drug Discovery & Development | 30/10/2025 | By Darshana
CEPI, SII and Oxford University Collaborate to Develop Nipah Virus Vaccine Reserve
CEPI, the Serum Institute of India, and the University of Oxford have partnered to produce ChAdOx1 NipahB vaccine doses for Phase II trials and an investigational reserve of up to 100,000 doses, ready for rapid deployment in case of a future Nipah outbreak.
Drug Discovery & Development | 30/10/2025 | By Dineshwori
Biogen licences Vanqua Bio's immune-disorder drug in deal worth up to USD 1.06 billion
Biogen has entered into an agreement with Vanqua Bio to acquire global rights to an experimental oral therapy for immune-related disorders, in a deal valued at up to USD 1.06 billion.
Drug Discovery & Development | 27/10/2025 | By Darshana
With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing – placing it among a handful of CDMOs with full-service capabilities.
Drug Discovery & Development | 24/10/2025 | By Darshana
Danish drugmaker Novo Nordisk has entered into a definitive asset purchase and license agreement with US-based Omeros Corporation for zaltenibart (formerly OMS906), a clinical-stage antibody therapy being developed for rare blood and kidney disorders.
Drug Discovery & Development | 16/10/2025 | By Dineshwori
EG BioMed Earns CAP Accreditation, Boosting YD Bio's Cancer Diagnostics
EG BioMed is one of YD Bio’s key licensing partners for pancreatic and breast cancer detection and collaborates with 3D Global to develop treatments for eye disorders.
Drug Discovery & Development | 13/10/2025 | By Darshana
India’s small and mid-sized pharmaceutical manufacturers are raising alarms over new good manufacturing practice (GMP) and bio-equivalence mandates, warning that the regulations could widen the gap between large companies and micro, small, and medium enterprises (MSMEs).
Drug Discovery & Development | 13/10/2025 | By Darshana | 191
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy